No-Cost, No-Obligation Zofran Birth Defects Lawsuit Review

 Zofran Lawsuits
Zofran Birth Defects Lawyers

New Report Released Intended To Advise Potential Zofran Plaintiffs.

The package released by The Medical Compensation Help Team reportedly takes potential Zofran birth defect plaintiffs through a series of tips to assist them in their pursuit of damages from GSK.

Wednesday, July 29, 2015 - A new report regarding the link between anti-nausea medication Zofran and its connection to birth defects has been released by The Medical Compensation Help Team. The free report is intended to assist women interesting in filing a lawsuit against the drug's manufacturer GlaxoSmithKline (GSK), advising against difference mistakes and procedural errors that might come up during the litigation process.

The report created by The Medical Compensation Help Team lists seven mistakes that can be made by plaintiffs when filing lawsuits against GSK relating to Zofran birth defect allegations. Some of these tips include hiring sound legal advice to assist with the litigative process and to be mindful of deadlines and claims windows set by the court. The report is available to interested parties upon request.

The report focuses on the rising litigation across the country taking aim at GSK for the off-label marketing of its medication Zofran for the treatment of morning sickness symptoms in pregnant mothers. A number of studies have cited Zofran research linking the drug to an increased risk of birth defects for the children of mothers who took the medication while pregnant. The alleged list of defects include heart and lung defects, cleft foot, cleft lips and a series of additional afflictions believe to be caused by Zofran use.

Zofran birth defect research performed by Harvard, Boston University and the medical journals Reproductive Toxicology and The New England Journal of Medicine have all discovered significant links between Zofran use and an increase in the risk for birth defects. A 2014 story published by the newspaper Toronto Star featured 20 Canadian women who had taken Zofran while pregnant and subsequently given birth to children with serious birth defects. Plaintiffs claim that given the amount of studies linking the drug to birth defects, GSK knew of the risk involved with their off-label marketing of the medication and proceeded to push its use for treating morning sickness.

Zofran was originally developed to be used as an anti-nausea medication for cancer patients after undergoing chemotherapy. However, GSK began to market the drugs off-label to physicians to be used to help relieve the symptoms of morning sickness. Zofran was never approved by the FDA for its prescription to pregnant mothers, but plaintiffs are claiming that GSK skipped this step in an effort to increase the revenue brought in by Zofran.

The giant pharmaceutical company was recently involved in a $3 billion settlement with the Department of Justice for taking similar steps with a number of medications that led to serious complications that were prescribed drugs for unapproved uses. Plaintiffs claim a similar strategy was followed in the prescribing of Zofran for morning sickness without FDA approval.

With lawsuits against GSK growing in number across the country, the company has recently filed a motion to transfer all of the claims into multidistrict litigation before the Judicial Panel on Multidistrict Litigation. This move indicates that GSK anticipates a large number of lawsuits to follow the handful that have been filed already, as the creation of an MDL is a step taken to help the litigative process for large, nationwide lawsuits that share common questions of fact. It is also indicative of GSK's position in the claims as it is not as common for a defendant to file the motion to transfer lawsuits into multidistrict litigation.

More Recent Zofran Birth Defects Lawsuit News:

No-Cost, No-Obligation Zofran Birth Defect Lawsuit Case Review If You or a Loved One Has Had a Baby with Birth Defects

Onder, Shelton, O'Leary & Peterson, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. Onder, Shelton, O'Leary & Peterson has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others, and other law firms throughout the nation often seek its experience and expertise on complex litigation.